ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Creative Diagnostics Introduces Microneutralization Assay Service for Virus Detection

By: Get News
Creative Diagnostics recently introduced the Microneutralization Assay Service to support research labs in detecting virus-specific neutralizing antibodies from human and animal sera.

New York, USA - February 27, 2023 - As an expert in virology and microbiology, Creative Diagnostics recently introduced the Microneutralization Assay Service to support research labs in detecting virus-specific neutralizing antibodies from human and animal sera.

Measuring antibody titers against specific viruses is indispensable to virology and several assays have been exploited based on similar principles, i.e., serial dilutions of heat-inactivated serum are mixed with fixed virus and added to the appropriate cell line for incubation. Meanwhile, it is critical to keep the virus concentration low so as to detect infection and not saturate antibodies in the serum.

It is significant to ensure that the detection is independent of viral concentrations and dependent only on the concentration and potency of tested sera. Therefore, it is important to accurately identify the infectious units of each virus with clear readings without exceeding the limited number of antibodies, which can be achieved by testing different viral concentrations against a fixed neutralization concentration standard. In high-concentration serum, inhibitory factors may prevent infection independently; therefore, it is vital to obtain pure serum or serum immunized with vectors for baseline neutralization determination.

The neutralization test is the most accurate way to determine whether a person has antibodies that can neutralize the infectivity of a particular viral strain. Taking influenza viruses as an example, it detects antibodies targeting HA proteins of influenza viruses, thereby identifying functional strain-specific antibodies in human and animal sera. In addition, because viruses are contagious, they can be quickly analyzed once found.

Traditional influenza virus neutralization assays (based on inhibiting the formation of cytogenetic effects in MDCK cell culture) are time-consuming, laborious, and relatively slow. Creative Diagnostics' new Microneutralization Test provides researchers with high-quality results in two days using the ELISA microtiter plates, covering target virus and infected cell culture and microneutralization assay.

Creative Diagnostics combines its infection and analytical expertise to provide global clients with the strongest portfolio of antiviral and antibacterial in vitro testing services. In light of the growing needs of customers for novel antiviral and antibacterial compounds to treat infectious diseases, Creative Diagnostics is leveraging its expertise to perform in vitro testing for compounds, thus, estimating their potential efficacies using in vivo models.

If you have questions regarding the Microneutralization Assay Service or other In Vitro Antiviral Testing, please visit Creative Diagnostics at https://antiviral.creative-diagnostics.com.

About Creative Diagnostics

Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.

Media Contact
Company Name: Creative Diagnostics
Contact Person: Thomas Schmitt
Email: Send Email
Phone: 1-631-346-0027
Country: United States
Website: https://antiviral.creative-diagnostics.com



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.